Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: It has been proposed that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists used for the treatment of patients with type 2 diabetes might also improve their psoriasis. Objective: To assess the efficacy and safety of the GLP‐1R agonist liraglutide in glucose‐tolerant patients with plaque psoriasis. Methods: A total of 20 obese (body mass index > 25 kg/m 2), glucose‐tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1 : 1 to once‐daily subcutaneous injections with liraglutide or placebo for an 8‐week period. The primary end points were improvement in PASI and dermatology life quality index (DLQI). Secondary end points included changes in weight and high sensitive C‐reactive protein (hs CRP) levels, as well as adverse events. Results: After 8 weeks of treatment, no significant change in PASI was found in the liraglutide group (mean±standard deviation: −2.6 ± 2.1) compared with the placebo group (−1.3 ± 2.4) (P = 0.228). No difference in DLQI was observed between the groups [−2.5 ± 4.4 (liraglutide) vs. −3.7 ± 4.8 (placebo); P = 0.564]. Hs CRP did not change in any of the groups (0.26 ± 1 (placebo) vs. 0.25 ± 2.2 (liraglutide); P = 0.992). Liraglutide treatment resulted in a bodyweight loss of 4.7 ± 2.5 kg compared with 1.6 ± 2.7 kg in the placebo group (P = 0.014) accompanied by decreased cholesterol levels. No serious adverse events occurred during the 8‐week observation period. The most common complaint was transient nausea, which occurred in 45% of the liraglutide‐treated patients but in none from the placebo group. Conclusion: Liraglutide treatment for 8 weeks did not significantly change PASI, DLQI, or hs CRP in a small group of glucose‐tolerant obese patients with plaque psoriasis compared with placebo. A significant weight loss and decrease in cholesterol levels was observed in liraglutide‐treated patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
Drucker, D. J., & Rosen, C. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2297-z · Cited by 66
Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-011-0359-9 · Cited by 65
Self-citation
Research works printed but not linked: 14
- 10.2337/dc12-2330 · DOI
- 10.1001/archinte.167.15.1670 · DOI · Paper page
- 10.1111/j.1365-2796.2010.02310.x · DOI · Paper page
- 10.1016/B978-0-12-381517-0.00015-1 · DOI
- 10.1016/j.diabet.2011.11.004 · DOI
- 10.1111/j.1468-3083.2012.04609.x · DOI · Paper page
- 10.1111/bjd.12886 · DOI · Paper page
- 10.1111/exd.12081 · DOI · Paper page
- Reid CT, 2013, Liraglutide in combination with acitretin for severe recalcitrant psoriasis, Br J Dermatol, 169, 181
- 10.1001/jamadermatol.2013.722 · DOI · Paper page
- 10.1007/s00018-010-0396-5 · DOI
- 10.1016/j.bbrc.2009.10.015 · DOI · Paper page
- 10.1016/j.mehy.2011.09.011 · DOI
- 10.1161/01.CIR.0000132467.45278.59 · DOI · Paper page
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Two subsequent prospective studies found positive effects on psoriasis severity scores in type 2 diabetes patients treated with GLP-1 RAs [237,238], a finding that could not be confirmed in non-diabetes subjects [239].”
ResultGLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
Mazidi, M., Karimi, E., Rezaie, P., & Ferns, G. A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.022 · Cited by 89
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Guo, X., Zhou, Z., Lyu, X., Xu, H., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1844-1176 · Cited by 59
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021) · Revista de Investigación Clínica · doi:10.24875/ric.20000308 · Cited by 6
Metadata
- Authors
- Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C., Skov, L., Knop, F. K., & Vilsbøll, T.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2014-08-20
- Volume
- 29
- Issue
- 3
- Pages
- 555-559
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W2109769875
- Cited by
- 89
- References
- 11
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Novo Nordisk
- Aage Bangs Fond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.